ArticleUpsala journal of medical sciences2018

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.

Midori Kjellin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.